We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech ...
Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.
Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company’s disclosure that it received a Complete Response ...
Fintel on MSN
Jefferies downgrades Replimune Group (REPL)
Fintel reports that on April 13, 2026, Jefferies downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Buy to Hold. Analyst Price Forecast Suggests 641.98% Upside As of April 9, 2026, the ...
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma treatment for the second time, citing trial design issues.
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial ...
The U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, ...
Opinion
9dOpinion
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...
US biotech Replimune (Nasdaq: REPL) has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower ...
Dozens of Massachusetts workers are about to lose their jobs after the FDA rejected a promising cancer drug — for the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results